Johannes M. Heuckmann

7.1k total citations
21 papers, 1.3k citations indexed

About

Johannes M. Heuckmann is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Johannes M. Heuckmann has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Johannes M. Heuckmann's work include Lung Cancer Treatments and Mutations (13 papers), Cancer therapeutics and mechanisms (6 papers) and Cancer Genomics and Diagnostics (5 papers). Johannes M. Heuckmann is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer therapeutics and mechanisms (6 papers) and Cancer Genomics and Diagnostics (5 papers). Johannes M. Heuckmann collaborates with scholars based in Germany, United States and Czechia. Johannes M. Heuckmann's co-authors include Roman K. Thomas, William Pao, Christine M. Lovly, Martin L. Sos, Martin Peifer, Daniel Rauh, Mirjam Koker, Hyatt Balke‐Want, Lukas C. Heukamp and Heidi Chen and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cell and PLoS ONE.

In The Last Decade

Johannes M. Heuckmann

21 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johannes M. Heuckmann Germany 14 769 740 685 232 114 21 1.3k
Shigeki Nanjo Japan 22 713 0.9× 1.0k 1.4× 824 1.2× 317 1.4× 158 1.4× 54 1.6k
Susan Korenchuk United States 13 896 1.2× 462 0.6× 348 0.5× 204 0.9× 112 1.0× 18 1.4k
Jerry Haney United States 7 846 1.1× 296 0.4× 482 0.7× 362 1.6× 160 1.4× 12 1.2k
Eiji Iwama Japan 21 401 0.5× 1.2k 1.7× 1.5k 2.1× 348 1.5× 122 1.1× 70 1.9k
K. Papadopoulos United States 16 598 0.8× 215 0.3× 540 0.8× 131 0.6× 103 0.9× 56 1.1k
Hayriye V. Erkizan United States 15 657 0.9× 415 0.6× 236 0.3× 114 0.5× 125 1.1× 20 981
Emmy D.G. Fleuren Netherlands 17 497 0.6× 307 0.4× 368 0.5× 108 0.5× 98 0.9× 25 871
Vidya Nallasura United States 7 653 0.8× 566 0.8× 480 0.7× 178 0.8× 178 1.6× 10 1.3k
Sudha Parasuraman United States 12 438 0.6× 617 0.8× 695 1.0× 156 0.7× 128 1.1× 20 1.1k
Alexandra Eyzaguirre United States 8 722 0.9× 244 0.3× 564 0.8× 263 1.1× 101 0.9× 13 1.1k

Countries citing papers authored by Johannes M. Heuckmann

Since Specialization
Citations

This map shows the geographic impact of Johannes M. Heuckmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes M. Heuckmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes M. Heuckmann more than expected).

Fields of papers citing papers by Johannes M. Heuckmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johannes M. Heuckmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes M. Heuckmann. The network helps show where Johannes M. Heuckmann may publish in the future.

Co-authorship network of co-authors of Johannes M. Heuckmann

This figure shows the co-authorship network connecting the top 25 collaborators of Johannes M. Heuckmann. A scholar is included among the top collaborators of Johannes M. Heuckmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes M. Heuckmann. Johannes M. Heuckmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Majewska, Hanna, Piotr Czapiewski, Roopika Menon, et al.. (2020). ALK alterations in salivary gland carcinomas. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 478(5). 933–941. 17 indexed citations
2.
Sos, Martin L., Hannah L. Tumbrink, Carsten Schultz‐Fademrecht, et al.. (2019). Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.. Journal of Clinical Oncology. 37(15_suppl). e14718–e14718. 1 indexed citations
3.
Malchers, Florian, Meryem S. Ercanoglu, Roberta Castiglione, et al.. (2017). Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer. Clinical Cancer Research. 23(18). 5527–5536. 41 indexed citations
4.
Menon, Roopika, Erika Mariotti, Judith Mueller, et al.. (2017). PUB053 Panel Based Hybrid Capture Sequencing Assay to Correlate Mutational Load with Response to Immunotherapy. Journal of Thoracic Oncology. 12(1). S1478–S1479. 1 indexed citations
5.
Michels, Sebastian, Andreas H. Scheel, Thomas Wündisch, et al.. (2017). ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. npj Precision Oncology. 1(1). 4–4. 30 indexed citations
6.
Falk, Markus, Erika Mariotti, Miriam Bertrand, et al.. (2017). Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. Journal of Thoracic Oncology. 12(10). 1503–1511. 35 indexed citations
7.
Heitz, Florian, Sotirios Lakis, Philipp Harter, et al.. (2017). Cell-free tumor DNA in peri-operative blood samples from advanced high-grade serous ovarian cancer patients with and without complete resection.. Journal of Clinical Oncology. 35(15_suppl). 5555–5555. 1 indexed citations
8.
Menon, Roopika, Sotirios Lakis, Kenneth S. Thress, et al.. (2016). A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay. Journal of Thoracic Oncology. 11(9). e105–e107. 25 indexed citations
9.
Heukamp, Lukas C., et al.. (2016). 65P NEOliquid: Detection of KIF5B–RET fusions in liquid biopsy samples. Journal of Thoracic Oncology. 11(4). S82–S83. 4 indexed citations
10.
Majewska, Hanna, Judith Müller, Sotirios Lakis, et al.. (2016). Abstract 3190: Genomic profiling of salivary gland tumors identifies novel and targetable alterations. Cancer Research. 76(14_Supplement). 3190–3190. 1 indexed citations
11.
Rooney, Claire, Catherine Geh, Victoria Williams, et al.. (2016). Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. PLoS ONE. 11(2). e0149628–e0149628. 21 indexed citations
12.
Heuckmann, Johannes M. & Roman K. Thomas. (2015). A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Annals of Oncology. 26(9). 1830–1837. 37 indexed citations
13.
Richters, André, Julia Ketzer, Matthäus Getlik, et al.. (2013). Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry. 56(14). 5757–5772. 11 indexed citations
14.
Heuckmann, Johannes M., Hyatt Balke‐Want, Florian Malchers, et al.. (2012). Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. Clinical Cancer Research. 18(17). 4682–4690. 201 indexed citations
15.
Heuckmann, Johannes M., Daniel Rauh, & Roman K. Thomas. (2012). Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. Journal of Clinical Oncology. 30(27). 3417–3420. 48 indexed citations
16.
Heuckmann, Johannes M., Michael Hölzel, Martin L. Sos, et al.. (2011). ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clinical Cancer Research. 17(23). 7394–7401. 147 indexed citations
17.
Lovly, Christine M., Johannes M. Heuckmann, Elisa de Stanchina, et al.. (2011). Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors. Cancer Research. 71(14). 4920–4931. 177 indexed citations
18.
Sos, Martin L., Haridas B. Rode, Stefanie Heynck, et al.. (2010). Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation. Cancer Research. 70(3). 868–874. 175 indexed citations
19.
Muñoz, Iván, Anne‐Cécile Déclais, Mary Gardiner, et al.. (2009). Coordination of Structure-Specific Nucleases by Human SLX4/BTBD12 Is Required for DNA Repair. Molecular Cell. 35(1). 116–127. 268 indexed citations
20.
Koehl, Ulrike, Martina Mühlenhoff, Samir Tawadros, et al.. (2009). The Novel Chimeric Anti-NCAM (Neural Cell Adhesion Molecule) Antibody ch.MK1 Displays Antitumor Activity in SCID Mice but Does not Activate Complement-Dependent Cytolysis (CDC). Journal of Immunotherapy. 32(5). 442–451. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeki Nanjo Breakdown of academic impact, for papers by Susan Korenchuk Breakdown of academic impact, for papers by Jerry Haney Breakdown of academic impact, for papers by Eiji Iwama Breakdown of academic impact, for papers by K. Papadopoulos Breakdown of academic impact, for papers by Hayriye V. Erkizan Breakdown of academic impact, for papers by Emmy D.G. Fleuren Breakdown of academic impact, for papers by Vidya Nallasura Breakdown of academic impact, for papers by Sudha Parasuraman Breakdown of academic impact, for papers by Alexandra Eyzaguirre
Rankless by CCL
2026